Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4388438 | 1.00 | TRPV4 (0.32) | TRPV4CHRM2CHRM3L3MBTL1SMN1; SMN2 | |
| SCHEMBL4388433 | 1.00 | TRPV4 (0.32) | TRPV4CHRM2CHRM3L3MBTL1SMN1; SMN2 | |
| SCHEMBL4394332 | 0.84 | CHRM2 (0.34) | CHRM2CHRM3 | |
| SCHEMBL4394336 | 0.84 | CHRM2 (0.34) | CHRM2CHRM3 | |
| SCHEMBL4394334 | 0.84 | CHRM2 (0.34) | CHRM2CHRM3 | |
| SCHEMBL4391754 | 0.83 | MEN1 (0.38) | SMN1; SMN2 | |
| SCHEMBL4391757 | 0.83 | MEN1 (0.38) | SMN1; SMN2 | |
| SCHEMBL4391761 | 0.83 | MEN1 (0.38) | SMN1; SMN2 | |
| SCHEMBL4385191 | 0.83 | CHRM3 (0.33) | CHRM3 | |
| SCHEMBL4385194 | 0.83 | CHRM3 (0.33) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306059-A1 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-1889835-A1 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306059-A1 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP | CBR3, CNR1, C3AR1 | TRPV4 4090/4885CHRM2 13/4885CHRM3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.